



BAHA fluid exudates has closed as we have reached our target!

We are the highest recruiters in the UK for both TACTT3 and Butterfly trials!







TRIALS CURRENTLY OPEN

Acronym	Details	Recruitment (month)	Recruitment (total)
Accelerated PI Prof. H Mehanna	Enhance patients benefit by increasing the available cancer treatments options using co-ordinated platform to test new agents and repurposing existing pre-licenced therapeutic agents.	2	8
AMPACT2 PI Mr. P Monksfield	A TACTT3 study extension evaluating the safety of repeated quarterly treatment cycles with AM-101 for acute peripheral tinnitus	1	2
ART DECO PI Dr. P Sanghera	Investigating dose escalated IMRT in locally advanced laryngeal and hypopharyngeal cancers without unacceptable toxicity increases	1	29
BUTTERFLY PI Mr. P Monksfield	Post-market follow-up on the Cochlear™ Baha® Attract System (magnetic bone conduction implant) for Baha surgery candidates	3	9
COAST PI Dr. A Hartley	A phase II trial to determined whether aspirin can reduce hearing loss/ototoxicity for patients receiving high-dose cisplatin chemotherapy	0	12







TRIALS CURRENTLY OPEN

Acronym	Acronym Details		Recruitment (total)
Cost Effectiveness of BAHA PI Mr. P Monksfield	Assessing the benefit to patients of BAHA implantation and the cost effectiveness of using this device within the NHS	11	185
De-ESCALaTE HPV PI Dr. A Hartley	Determination of early and late toxicity events in treatment of HPV positive oropharyngeal SCC using cetuximab vs. cisplatin	1	24
HOPON PI Mr. P Praveen	A randomised controlled trial investigating the use of hyperbaric oxygen to prevent osteoradionecrosis of the irradiated mandible	0	11
IoN PI Prof. H Mehanna	A phase II/III trial investigating the necessity of ablative radio-iodine for treatment of low risk differentiated thyroid cancer patients	0	0
NIMRAD A phase III trial determining whether HNSCC patients unsuitable for cisplatin/cetuximab can benefit from nimorazole with standard RT		0	6







TRIALS CURRENTLY OPEN

Acronym	Details	Recruitment (month)	Recruitment (total)
OROMOUTH PI Mr. S Ahmed	Determining the prevalence of HPV in the mouth and oropharynx of the tonsillectomy population using tonsils, oral fluid, blood and urine	4	164
QUIET PI Miss. R Banga	A Balanced Randomised Placebo Controlled Double-blind Phase IIa Study to Investigate the Efficacy and Safety of AUT00063 Versus Placebo in Subjective Tinnitus.	0	0
RAPPER Pl Dr. A Hartley	Assessing the association between DNA polymorphisms and individual patient variability in normal tissue radiation response and toxicity	0	24
SEND PI Mr. P Praveen	Investigating the role of selective neck dissection for patients with early oral SCC (T1/T2) and no clinical evidence of lymph node metastases	0	27
TACTT3 PI Mr. P Monksfield	A phase III trial to evaluate the efficacy of repeated AM-101 (esketamine hydrochloride) gel injections for acute peripheral tinnitus	0	10
TRISMUS PI Mrs. V Harrop	A randomised pilot study of TheraBite® device vs. wooden spatula in the amelioration of trismus (lockjaw) in head and neck cancer patients	0	6





PENDING TRIALS

P	Acronym	Details
	compARE of. H Mehanna	A phase III randomised controlled trial comparing alternative regimens for escalating treatment of higher-risk oropharyngeal cancer
	hANCA-21 Ir. P Praveen	A phase III randomised study to assess the effect of hyperbaric oxygen on mandibular osteoradionecrosis as an adjunctive to surgical treatment in patients previously irradiated for head and neck cancer
	ElaTION of. H Mehanna	A randomised study investigating study looking at the efficacy and cost effectiveness of real time ultrasound elastography in the investigations of thyroid nodules and the diagnosis of thyroid cancer
PIM	MorEx Mr. A Hartley	A commercial phase I exploratory study to evaluate safety and efficacy of MTL-005, a photodynamic therapeutic agent, as a radiosensitizer for patients with advanced carcinoma of the head and neck indicated for palliative radiotherapy
PI Pro	NATT of. H Mehanna	Collecting tissue and blood samples from anaplastic thyroid cancer patients, as well as anoymised clinical data, to help establish a national tissue bank and database to facilitate basic and translational research opportunities
100	OTO-104 Ar R Irving	Placebo-controlled safety study, Double-blind (First 6 months), Randomized, Multi-center, followed by a 6-month open label extension
	PACIFIC Dr. A Hartley	An early phase dose escalation study to establish a safe dose for siRNA formulation ATU027 in combination with the standard treatment of cisplatin, 5-FU and cetuximab for head and neck cancer





Thank you for your continued support!

If you have any comments regarding the News letter Please contact me Janeil on 0121 414-9276

Email: janeil.hutchinson@uhb.nhs.uk

